Formycon AG (FYB) - Total Assets
Based on the latest financial reports, Formycon AG (FYB) holds total assets worth €739.53 Million EUR (≈ $864.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore FYB operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Formycon AG - Total Assets Trend (2009–2025)
This chart illustrates how Formycon AG's total assets have evolved over time, based on quarterly financial data. See Formycon AG net assets for net asset value and shareholders' equity analysis.
Formycon AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Formycon AG's total assets of €739.53 Million consist of 16.9% current assets and 83.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 9.3% |
| Accounts Receivable | €32.27 Million | 4.4% |
| Inventory | €2.05 Million | 0.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €414.03 Million | 56.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Formycon AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see FYB company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Formycon AG's current assets represent 16.9% of total assets in 2025, a decrease from 92.4% in 2009.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, up from 1.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 6.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 56.0% of total assets.
Formycon AG Competitors by Total Assets
Key competitors of Formycon AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Formycon AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 2.80 | 10.06 |
| Quick Ratio | 2.30 | 2.80 | 9.82 |
| Cash Ratio | 0.00 | 1.23 | 0.00 |
| Working Capital | €71.47 Million | €61.13 Million | €45.49 Million |
Formycon AG - Advanced Valuation Insights
This section examines the relationship between Formycon AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.83 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | -4.2% |
| Total Assets | €739.53 Million |
| Market Capitalization | $336.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Formycon AG's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Formycon AG's assets decreased by 4.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Formycon AG (2009–2025)
The table below shows the annual total assets of Formycon AG from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €739.53 Million ≈ $864.58 Million |
-4.17% |
| 2024-12-31 | €771.72 Million ≈ $902.22 Million |
-13.33% |
| 2023-12-31 | €890.36 Million ≈ $1.04 Billion |
+4.29% |
| 2022-12-31 | €853.70 Million ≈ $998.06 Million |
+1107.24% |
| 2021-12-31 | €70.72 Million ≈ $82.67 Million |
-6.46% |
| 2020-12-31 | €75.60 Million ≈ $88.38 Million |
+41.16% |
| 2019-12-31 | €53.56 Million ≈ $62.61 Million |
+35.16% |
| 2018-12-31 | €39.62 Million ≈ $46.32 Million |
+28.53% |
| 2017-12-31 | €30.83 Million ≈ $36.04 Million |
+22.40% |
| 2016-12-31 | €25.19 Million ≈ $29.45 Million |
-7.22% |
| 2015-12-31 | €27.15 Million ≈ $31.74 Million |
+60.58% |
| 2014-12-31 | €16.91 Million ≈ $19.77 Million |
+9.46% |
| 2013-12-31 | €15.44 Million ≈ $18.06 Million |
+102.17% |
| 2012-12-31 | €7.64 Million ≈ $8.93 Million |
+36.57% |
| 2011-12-31 | €5.59 Million ≈ $6.54 Million |
+30.71% |
| 2010-12-31 | €4.28 Million ≈ $5.00 Million |
+510.49% |
| 2009-12-31 | €701.00K ≈ $819.54K |
-- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more